{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:26:28Z","timestamp":1789680388303,"version":"4.0.1"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Two recent Phase 3 trials demonstrated the efficacy of gepotidacin compared with nitrofurantoin to treat uncomplicated urinary tract infections (uUTIs) in females. Pretreatment urine specimens were obtained from all participants. Based on pooled trial data (treatment groups combined), central laboratory culture results identified 1,421 (45%) participants with \u22651 baseline qualifying (\u226510\n              <jats:sup>5<\/jats:sup>\n              CFU\/mL) uropathogen (i.e., pooled microbiological Intent-to-Treat population).\n              <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n              ,\n              <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n              , and\n              <jats:italic toggle=\"yes\">Proteus mirabilis<\/jats:italic>\n              were the most common qualifying uropathogens. Among 1,159\n              <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n              isolates, 28%, 28%, 15%, and 28% were fluoroquinolone resistant (FQ-R), trimethoprim-sulfamethoxazole resistant (SXT-R), extended-spectrum \u03b2-lactamase positive (ESBL+), and multidrug resistant (MDR), respectively. For 114\n              <jats:italic toggle=\"yes\">K<\/jats:italic>\n              .\n              <jats:italic toggle=\"yes\">pneumoniae<\/jats:italic>\n              isolates, 25%, 23%, 16%, and 16% were nitrofurantoin resistant, SXT-R, FQ-R, and ESBL+, respectively. Of 67\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              .\n              <jats:italic toggle=\"yes\">mirabilis<\/jats:italic>\n              isolates, 25%, 21%, and 31% were SXT-R, FQ-R, and MDR, respectively. Gepotidacin MIC\n              <jats:sub>90<\/jats:sub>\n              values against all qualifying uropathogens and drug-resistant phenotypes ranged from 0.25 to 32 \u00b5g\/mL, with no isolates of Enterobacterales,\n              <jats:italic toggle=\"yes\">Staphylococcus saprophyticus<\/jats:italic>\n              , or\n              <jats:italic toggle=\"yes\">Enterococcus faecalis<\/jats:italic>\n              considered resistant to gepotidacin. For all uropathogen drug-resistant phenotypes, gepotidacin MIC\n              <jats:sub>90<\/jats:sub>\n              values were similar (i.e., lower, equal to, or 1-dilution higher) compared with the MIC\n              <jats:sub>90<\/jats:sub>\n              of the overall species. Gepotidacin\u2019s efficacy, based on therapeutic, clinical, and microbiological success rates, was generally consistent across phenotypic subgroups of\n              <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n              ,\n              <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n              , and\n              <jats:italic toggle=\"yes\">P. mirabilis<\/jats:italic>\n              . This pooled analysis represents a robust, contemporary, clinically relevant, and unbiased (i.e., baseline urine specimens obtained from all enrolled participants regardless of uUTI history) collection of data from community-acquired uUTIs in females.\n            <\/jats:p>\n            <jats:sec>\n              <jats:title>CLINICAL TRIALS<\/jats:title>\n              <jats:p>\n                This study is registered with ClinicalTrials.gov as\n                <jats:related-object xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" document-id=\"NCT04020341\" document-id-type=\"clinical-trial-number\" source-id=\"ClinicalTrials.gov\" source-id-type=\"registry-name\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04020341\">NCT04020341<\/jats:related-object>\n                and\n                <jats:related-object xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" document-id=\"NCT04187144\" document-id-type=\"clinical-trial-number\" source-id=\"ClinicalTrials.gov\" source-id-type=\"registry-name\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04187144\">NCT04187144<\/jats:related-object>\n                .\n              <\/jats:p>\n            <\/jats:sec>\n          <\/jats:sec>","DOI":"10.1128\/aac.01640-24","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T14:44:40Z","timestamp":1757429080000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and\n            <i>in vitro<\/i>\n            activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3)"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4211-8261","authenticated-orcid":true,"given":"Nicole E.","family":"Scangarella-Oman","sequence":"first","affiliation":[{"name":"GSK","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah L.","family":"Butler","sequence":"additional","affiliation":[{"name":"GSK","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Breton","sequence":"additional","affiliation":[{"name":"GSK","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrek","family":"Brown","sequence":"additional","affiliation":[{"name":"GSK","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Kasapidis","sequence":"additional","affiliation":[{"name":"GSK","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Millns","sequence":"additional","affiliation":[{"name":"GSK","place":["Stevenage, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Huang","sequence":"additional","affiliation":[{"name":"GSK","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Perry","sequence":"additional","affiliation":[{"name":"GSK","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3115-5016","authenticated-orcid":false,"given":"Amanda J.","family":"Sheets","sequence":"additional","affiliation":[{"name":"GSK","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-0614","authenticated-orcid":false,"given":"Jeremy","family":"Dennison","sequence":"additional","affiliation":[{"name":"GSK","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Janmohamed","sequence":"additional","affiliation":[{"name":"GSK","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12040623"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756287219832172"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3432"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2010.190"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2013.09.003"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220265"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab560"},{"key":"e_1_3_4_9_2","unstructured":"Centers for Disease Control and Prevention. 2019. Antibiotic resistance threats in the United States 2019. https:\/\/www.cdc.gov\/antimicrobial-resistance\/media\/pdfs\/2019-ar-threats-report-508.pdf?CDC_AAref_Val=https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf."},{"key":"e_1_3_4_10_2","unstructured":"World Health Organization. 2024. WHO bacterial priority pathogens list 2024: bacterial pathogens of public health importance to guide research development and strategies to prevent and control antimicrobial resistance. https:\/\/iris.who.int\/handle\/10665\/376776."},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02196-7"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00315"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.3c00346"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00207-19"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01525-22"},{"key":"e_1_3_4_17_2","volume-title":"Abstr 29th ECCMID","author":"Mushtaq S","year":"2019","unstructured":"Mushtaq S, Vickers A, Sadouki Z, Cole M, Fifer H, Donascimento V, Day M, Pinna E, Jenkins C, Godbole G, Woodford N. 2019. In vitro activities of gepotidacin, a novel triazaacenaphthylene and topoisomerase IV DNA gyrase inhibitor, against Gram-negative bacteria and Staphylococcus saprophyticus, poster P1849. Abstr 29th ECCMID. Amsterdam, The Netherlands"},{"key":"e_1_3_4_18_2","unstructured":"GSK. 2025. Blujepa (gepotidacin). Package insert"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00706-9"},{"key":"e_1_3_4_20_2","volume-title":"M100Ed32Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2022","unstructured":"Clinical and Laboratory Standards Institute. 2022. M100Ed32. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_21_2","article-title":"Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including subsets with molecularly characterized resistance mechanisms and genotypes\/epidemiological clones, in females with uncomplicated urinary tract infections: results from two global pivotal phase 3 trials (EAGLE-2 and EAGLE-3)","author":"Scangarella-Oman NE","year":"2025","unstructured":"Scangarella-Oman NE, Butler DL, Breton J, Brown D, Kasapidis C, Sheets AJ. 2025. Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including subsets with molecularly characterized resistance mechanisms and genotypes\/epidemiological clones, in females with uncomplicated urinary tract infections: results from two global pivotal phase 3 trials (EAGLE-2 and EAGLE-3). Antimicrob Agents Chemother In press.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_22_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2022. Breakpoint tables for interpretation of MICs and zone diameters version 12.0. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_12.0_Breakpoint_Tables.pdf"},{"key":"e_1_3_4_23_2","unstructured":"Food and Drug Administration. 2025. Antibacterial susceptibility test interpretive criteria. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria. Retrieved 14 Apr 2025."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.1305"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.05.016"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_4_27_2","volume-title":"M07Ed11Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. M07Ed11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute, Wayne, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01640-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01640-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:01:21Z","timestamp":1759323681000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01640-24"}},"subtitle":[],"editor":[{"given":"Ryan K.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1128\/aac.01640-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.01640-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2024-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01640-24"}}